146 related articles for article (PubMed ID: 37042459)
1. Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma.
Erul E; Guven DC; Ozbay Y; Altunbulak AY; Kahvecioglu A; Ercan F; Yesil MF; Ucdal MT; Cengiz M; Yazici G; Kuscu O; Suslu N; Gullu I; Onur MR; Aksoy S
Biomark Med; 2023 Jan; 17(2):87-99. PubMed ID: 37042459
[TBL] [Abstract][Full Text] [Related]
2. The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy.
Bentahila R; Giraud P; Decazes P; Kreps S; Nay P; Chatain A; Fabiano E; Durdux C
Cancer Med; 2023 Feb; 12(4):4170-4183. PubMed ID: 36263581
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of sarcopenia and sarcopenic obesity in patients affected by oral squamous cell carcinoma: A retrospective single-center study.
Bonavolontà P; Improta G; Dell'Aversana Orabona G; Goglia F; Abbate V; Sorrentino A; Piloni S; Salzano G; Iaconetta G; Califano L
J Craniomaxillofac Surg; 2023 Jan; 51(1):7-15. PubMed ID: 36739189
[TBL] [Abstract][Full Text] [Related]
4. Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience.
Nagpal P; Pruthi DS; Pandey M; Yadav A; Singh H
Oral Oncol; 2021 Oct; 121():105483. PubMed ID: 34403887
[TBL] [Abstract][Full Text] [Related]
5. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy.
van Rijn-Dekker MI; van den Bosch L; van den Hoek JGM; Bijl HP; van Aken ESM; van der Hoorn A; Oosting SF; Halmos GB; Witjes MJH; van der Laan HP; Langendijk JA; Steenbakkers RJHM
Radiother Oncol; 2020 Jun; 147():103-110. PubMed ID: 32251949
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.
Jung AR; Roh JL; Kim JS; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2019 Jul; 116():98-106. PubMed ID: 31185387
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma.
Nishikawa D; Hanai N; Suzuki H; Koide Y; Beppu S; Hasegawa Y
ORL J Otorhinolaryngol Relat Spec; 2018; 80(1):1-9. PubMed ID: 29393251
[TBL] [Abstract][Full Text] [Related]
8. Association of Sarcopenia With Oncologic Outcomes of Primary Surgery or Definitive Radiotherapy Among Patients With Localized Oropharyngeal Squamous Cell Carcinoma.
Olson B; Edwards J; Stone L; Jiang A; Zhu X; Holland J; Li R; Andersen P; Krasnow S; Marks DL; Clayburgh D
JAMA Otolaryngol Head Neck Surg; 2020 Aug; 146(8):714-722. PubMed ID: 32525518
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
Chargi N; Bril SI; Swartz JE; Wegner I; Willems SM; de Bree R
Oral Oncol; 2020 Feb; 101():104519. PubMed ID: 31855705
[TBL] [Abstract][Full Text] [Related]
10. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
[TBL] [Abstract][Full Text] [Related]
11. Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment.
Ahern E; Brown TE; Campbell L; Hughes BGM; Banks M; Lin CY; Kenny LM; Bauer J
Br J Nutr; 2023 Feb; 129(3):406-415. PubMed ID: 35152926
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
[TBL] [Abstract][Full Text] [Related]
13. Sarcopenia at the infrahyoid level as a prognostic factor in patients with advanced-stage non-virus-related head and neck carcinoma.
Yunaiyama D; Okubo M; Arizono E; Tsukahara K; Tanigawa M; Nagao T; Saito K
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3131-3137. PubMed ID: 34697649
[TBL] [Abstract][Full Text] [Related]
14. Association between pretreatment obesity, sarcopenia, and survival in patients with head and neck cancer.
Fattouh M; Chang GY; Ow TJ; Shifteh K; Rosenblatt G; Patel VM; Smith RV; Prystowsky MB; Schlecht NF
Head Neck; 2019 Mar; 41(3):707-714. PubMed ID: 30582237
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancer.
Yamahara K; Mizukoshi A; Lee K; Ikegami S
Auris Nasus Larynx; 2021 Oct; 48(5):1013-1022. PubMed ID: 33883097
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
17. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy.
Shodo R; Yamazaki K; Ueki Y; Takahashi T; Horii A
Eur Arch Otorhinolaryngol; 2021 Jun; 278(6):2001-2009. PubMed ID: 32772234
[TBL] [Abstract][Full Text] [Related]
19. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation.
Ganju RG; Morse R; Hoover A; TenNapel M; Lominska CE
Radiother Oncol; 2019 Aug; 137():117-124. PubMed ID: 31085391
[TBL] [Abstract][Full Text] [Related]
20. CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer.
Zwart AT; van der Hoorn A; van Ooijen PMA; Steenbakkers RJHM; de Bock GH; Halmos GB
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1060-1069. PubMed ID: 31134765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
